Nuvonis is a biotech company providing innovative cell banks for vaccine and vector production that will dramatically speed up your development. Nuvonis' experienced team provides technical support for virus production processes and vaccine strain improvement.
Nuvonis Avian Cell Banks (R&D and GMP)
Avian cells are suitable for the production of a variety of viruses, such as Vaccinia, Orthomyxoviridae, HSV Type I, Pseudorabies, Reovirus, Parainfluenza, Newcastle Disease Virus, MVA etc. Importantly, avian cell lines can replace Chicken Embryo Fibroblasts (CEF) or cultivation of viruses in embryonated hen’s eggs. Nuvonis has developed a novel continuous avian cell line (CCX) from primary quail (Coturnix japonica). Nuvonis avian cell banks are available both for adherent growth and growth in suspension.
Nuvonis Vero Cell Banks (R&D and GMP)
Vero cells are widely used for manufacturing a variety of viruses and vectors. Nuvonis provides “ready to use” GMP Master and GMP Working Cell Banks. Vero cell banks are produced under serum and animal-free media conditions. Vero cell banks are immediately available for GMP manufacturing and are fully characterized including tumorigenicity testing at the end of production level (EPCB).
Process Development Services
The Nuvonis team is highly experienced in developing and optimizing up- and downstream vaccine production processes and all aspects of vaccine development. Amongst other optimization techniques, we are offering a proprietary and efficient virus purification process for the generation of high-purity vaccine bulk drug substance, meeting regulatory requirements in terms of host cell DNA and host cell protein impurities.
Advantages
Why Nuvonis?
Rely on Cell Banks that are ready to use
Shorten the clinical evaluation timelines of your vaccine candidate and reduce time to market by 1-2 years. Save time and money, and rely on our experience!
Rely on fully characterized GMP compliant Cell Banks
Minimize your development risks by using a state-of-the-art cell bank that is fully tested according to international guidelines (US FDA cGMP – 21 Code of Federal Regulations, European Pharmacopoeia and ICH guidelines)
Latest blog articles
Nuvonis´ New Process for the Production and Purification of Newcastle Disease Virus as Alternative to Egg-based Production
Nuvonis has developed a new high-yield platform process for the production and purification of Newcastle disease virus (NDV). The process is based on a novel avian cell line CCX.E10, an alternative to traditional egg-based production and monolith chromatography for purification. This allows for robust manufacturing and enables new NDV product development. What is Newcastle Disease?
hVIVO Used Nuvonis GMP Vero Cells to Produce Novel SARS-CoV-2 Virus for a Human Challenge Model
One of the main benefits of using Nuvonis fully tested GMP Vero cells is the unparalleled speed towards clinical trials. A case example from one of our customers, hVIVO: First contact with Nuvonis in July 2020, due diligence, contracting, provision of GMP Vero cells and protocols, as well as full documentation Production of GMP material
The novel suspension quail cell line CCX.E10 is an ideal cell substrate for NDV virus and vector production
The Novel Suspension Quail Cell Line CCX.E10 Is an Ideal Cell Substrate for Newcastle Disease Virus (NDV) and Vector Production Newcastle disease is a highly infectious viral disease of the avian species. The causative agent is Newcastle disease virus (NDV), which belongs to the family of Paramyxoviridae. Many commercial vaccines, both live and inactivated, are